Pasithea Therapeutics (KTTA) said Thursday that the external Safety Review Committee recommended that the company's phase 1 clinical trial of PAS-004, a next-generation macrocyclic MEK inhibitor, in advanced cancer should proceed to cohort 6, 30mg capsules, without any modification.
The recommendation was based on the review of the safety data from three patients from cohort 5 and the absence of any dose limiting toxicities, or DLT, the biotechnology company said.
During the DLT period, no rash was observed to date in any of the first 19 patients in either capsule or tablet formulation of PAS-004. Rash is a common adverse event that is observed at low doses with competitor MEK inhibitors, Pasithea said.
Shares were up 50% in early Thursday trading.
Price: 1.62, Change: +0.54, Percent Change: +50.00
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。